Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (<i>Raja undulata</i>)

The therapy database currently used in elasmobranchs is still mostly based on empirical data, and there are few efficacy and safety studies supporting clinical practice. In this study, meloxicam pharmacokinetics (PK) were evaluated after a single 1.5 mg/kg IM administration to a group of seven clini...

Full description

Bibliographic Details
Main Authors: Pablo Morón-Elorza, Daniela Cañizares-Cooz, Carlos Rojo-Solis, Teresa Álvaro-Álvarez, Mónica Valls-Torres, Daniel García-Párraga, Teresa Encinas
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Veterinary Sciences
Subjects:
Online Access:https://www.mdpi.com/2306-7381/9/5/216
_version_ 1797494744040865792
author Pablo Morón-Elorza
Daniela Cañizares-Cooz
Carlos Rojo-Solis
Teresa Álvaro-Álvarez
Mónica Valls-Torres
Daniel García-Párraga
Teresa Encinas
author_facet Pablo Morón-Elorza
Daniela Cañizares-Cooz
Carlos Rojo-Solis
Teresa Álvaro-Álvarez
Mónica Valls-Torres
Daniel García-Párraga
Teresa Encinas
author_sort Pablo Morón-Elorza
collection DOAJ
description The therapy database currently used in elasmobranchs is still mostly based on empirical data, and there are few efficacy and safety studies supporting clinical practice. In this study, meloxicam pharmacokinetics (PK) were evaluated after a single 1.5 mg/kg IM administration to a group of seven clinically healthy adult undulate skates (<i>Raja undulata</i> Lacepède, 1802). Blood samples were collected before administration and at 15, 30, 60 and 90 min and 2, 4, 8, 12, 24 and 48 h after the IM injection. The meloxicam concentrations in plasma were determined using high-performance liquid chromatography, and PK parameters were calculated using a non-compartmental model approach. The mean ± SEM values of the main PK values were 1.84 ± 0.31 μg/mL for peak plasma concentration, 1.5 ± 0.24 h for time to maximum plasma concentration, 11.43 ± 2.04 h·µg/mL for area under the plasma concentration vs. time curve, 3.55 ± 0.65 h for elimination half-life, and 5.37 ± 0.94 h for mean residency time. No adverse reactions were detected. The relatively high plasma concentration and short time to maximum plasma concentration suggest that meloxicam could turn into an efficient analgesic and anti-inflammatory candidate drug to be used in skates. Further efficacy, pharmacodynamic, and multiple-dose studies with meloxicam are needed in elasmobranchs.
first_indexed 2024-03-10T01:38:46Z
format Article
id doaj.art-bc8ce761cee8471b8169b2a8649d8532
institution Directory Open Access Journal
issn 2306-7381
language English
last_indexed 2024-03-10T01:38:46Z
publishDate 2022-04-01
publisher MDPI AG
record_format Article
series Veterinary Sciences
spelling doaj.art-bc8ce761cee8471b8169b2a8649d85322023-11-23T13:28:21ZengMDPI AGVeterinary Sciences2306-73812022-04-019521610.3390/vetsci9050216Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (<i>Raja undulata</i>)Pablo Morón-Elorza0Daniela Cañizares-Cooz1Carlos Rojo-Solis2Teresa Álvaro-Álvarez3Mónica Valls-Torres4Daniel García-Párraga5Teresa Encinas6Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Complutense University of Madrid, Av. Puerta de Hierro s/n, 28040 Madrid, SpainDepartment of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Complutense University of Madrid, Av. Puerta de Hierro s/n, 28040 Madrid, SpainVeterinary Services, Oceanogràfic, Ciudad de las Artes y las Ciencias, C/Eduardo Primo Yúfera (Científic) 1B, 46013 Valencia, SpainVeterinary Services, Oceanogràfic, Ciudad de las Artes y las Ciencias, C/Eduardo Primo Yúfera (Científic) 1B, 46013 Valencia, SpainVeterinary Services, Oceanogràfic, Ciudad de las Artes y las Ciencias, C/Eduardo Primo Yúfera (Científic) 1B, 46013 Valencia, SpainFundación Oceanogràfic de la Comunitat Valenciana, C/Eduardo Primo Yúfera (Científic) 1B, 46013 Valencia, SpainDepartment of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Complutense University of Madrid, Av. Puerta de Hierro s/n, 28040 Madrid, SpainThe therapy database currently used in elasmobranchs is still mostly based on empirical data, and there are few efficacy and safety studies supporting clinical practice. In this study, meloxicam pharmacokinetics (PK) were evaluated after a single 1.5 mg/kg IM administration to a group of seven clinically healthy adult undulate skates (<i>Raja undulata</i> Lacepède, 1802). Blood samples were collected before administration and at 15, 30, 60 and 90 min and 2, 4, 8, 12, 24 and 48 h after the IM injection. The meloxicam concentrations in plasma were determined using high-performance liquid chromatography, and PK parameters were calculated using a non-compartmental model approach. The mean ± SEM values of the main PK values were 1.84 ± 0.31 μg/mL for peak plasma concentration, 1.5 ± 0.24 h for time to maximum plasma concentration, 11.43 ± 2.04 h·µg/mL for area under the plasma concentration vs. time curve, 3.55 ± 0.65 h for elimination half-life, and 5.37 ± 0.94 h for mean residency time. No adverse reactions were detected. The relatively high plasma concentration and short time to maximum plasma concentration suggest that meloxicam could turn into an efficient analgesic and anti-inflammatory candidate drug to be used in skates. Further efficacy, pharmacodynamic, and multiple-dose studies with meloxicam are needed in elasmobranchs.https://www.mdpi.com/2306-7381/9/5/216elasmobranchchondrichthyanpainanalgesiaNSAIDHLPC
spellingShingle Pablo Morón-Elorza
Daniela Cañizares-Cooz
Carlos Rojo-Solis
Teresa Álvaro-Álvarez
Mónica Valls-Torres
Daniel García-Párraga
Teresa Encinas
Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (<i>Raja undulata</i>)
Veterinary Sciences
elasmobranch
chondrichthyan
pain
analgesia
NSAID
HLPC
title Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (<i>Raja undulata</i>)
title_full Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (<i>Raja undulata</i>)
title_fullStr Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (<i>Raja undulata</i>)
title_full_unstemmed Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (<i>Raja undulata</i>)
title_short Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (<i>Raja undulata</i>)
title_sort pharmacokinetics of the anti inflammatory drug meloxicam after single 1 5 mg kg intramuscular administration to undulate skates i raja undulata i
topic elasmobranch
chondrichthyan
pain
analgesia
NSAID
HLPC
url https://www.mdpi.com/2306-7381/9/5/216
work_keys_str_mv AT pablomoronelorza pharmacokineticsoftheantiinflammatorydrugmeloxicamaftersingle15mgkgintramuscularadministrationtoundulateskatesirajaundulatai
AT danielacanizarescooz pharmacokineticsoftheantiinflammatorydrugmeloxicamaftersingle15mgkgintramuscularadministrationtoundulateskatesirajaundulatai
AT carlosrojosolis pharmacokineticsoftheantiinflammatorydrugmeloxicamaftersingle15mgkgintramuscularadministrationtoundulateskatesirajaundulatai
AT teresaalvaroalvarez pharmacokineticsoftheantiinflammatorydrugmeloxicamaftersingle15mgkgintramuscularadministrationtoundulateskatesirajaundulatai
AT monicavallstorres pharmacokineticsoftheantiinflammatorydrugmeloxicamaftersingle15mgkgintramuscularadministrationtoundulateskatesirajaundulatai
AT danielgarciaparraga pharmacokineticsoftheantiinflammatorydrugmeloxicamaftersingle15mgkgintramuscularadministrationtoundulateskatesirajaundulatai
AT teresaencinas pharmacokineticsoftheantiinflammatorydrugmeloxicamaftersingle15mgkgintramuscularadministrationtoundulateskatesirajaundulatai